State Grid Hangzhou Power Supply Company Introduces "Green Power Water Purifier" to Pave the Path for Tibetan Children to School
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients wit
SIMS METAL ACQUIRES NORTHEAST METAL TRADERS
The value of community in the crypto space: Myntfund
Ivanti Appoints Steve Marconi as VP Partner Sales, Americas and Dean Beaver, VP Strategic Alliances as Part of its Global Channels & Alliances Leaders
Rokid Unveils Rokid Max AR Glasses With Premium MAX-Theater Experience
Olilawn Launches Its Pergola Series Coming with a New Arched Pergola Product
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
U.S. XPRESS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed
PTT Oil and Retail Business (OR) reports over 50% income growth in 2022, allocating $900 million investment for local and international business in 20
-
BuildTech Asia 2023 to focus on Digitalisation, Smart Building & Construction and Sustainability
SINGAPORE, March 22, 2023 /PRNewswire/ -- BuildTech Asia (BTA), the leading platform for Asia Pacific's building and construction industry, is back for its 12th edition from 28 – 30 March 2023. A Constellar event, BTA's theme this year is "Transforming Tomorrow's Built Environment", presented with 48 local and regional industry associations and partners. BTA 2023 will feature over 100 onsite exhibitors from 15 countries and regions (almost a 40% expansion from last year) and an extensive line-up of conferences, sandboxes and product launches to better equip and future-proof the sector. Countries and regions participating include Singapore, Australia, Cambodia, Mainland China, Finland, Germany, Hong Kong, India, Israel, Japan, Korea, Malaysia, Poland, Sweden, Taiwan and USA. Official Launch of BCA – STAS Shared Services Providers (SSP) Scheme Guest-of-Honour Senior Minister of State for Ministry of Communications and Information & Ministry of National Development Mr Tan Kiat How will officiate the opening of BTA 2023 with an opening address and the official launch of Specialists Trade Alliance of Singapore (STAS)'s Shared Services Registry, a significant milestone in STAS's commitment to digitalising the Built Environment sector. The adoption of Building Information Modelling (BIM) and Integrated Digital Delivery (IDD) is a key enabler of transformation in the Built Environment sector. It is a digital spine that links project stakeholders throughout the entire building lifecycle. The Shared Services Registry serves the BIM and IDD procurement needs of stakeholders, especially SMEs, in their digitalisation journey. The pilot was successful, and the Shared Services Registry will be scaled up to implement more rigorous quality checks and open up for public registration from Q3 2023. Experience Tomorrow's Built Environment in person BTA 2023 will deep-dive into three dimensions of emerging technologies and solutions that are making an impact on industries today - Digitalisation, Smart Construction (Robotics & Automation) & Green Construction (Sustainability). To better demonstrate the utilisation of new technologies and solutions, BTA 2023 has curated and will be introducing two new experiential zones: The Smart Construction Experience Zone, powered by Tractors Singapore Limited (TSL), a leading equipment dealer in Singapore distributing a full line of Cat® machines and engines such as the Excavator 320 and the Vibratory Soil Compactor CS11GC; The Robotics & Automation Experience Zone, featuring Singapore SMEs such as Doog International, who will be showcasing their user-friendly and highly scalable autonomous mobile robots such as "THOUZER", a versatile robotic cart with a payload capacity of 120kg, a towing capacity of 300kg and equipped with Follow-Me and Memory Trace® Technology, developed to navigate challenging construction work sites and execute automated repetitive tasks. BTA 2023 will also welcome new companies offering their latest solutions, equipment and machinery for the sector: Knauf Plasterboard Ptd Ltd: one of the world's leading dry construction systems and solutions providers Liugong Machinery Co., Ltd: 10th-largest construction equipment manufacturer by global market share and the world's largest manufacturer of wheel loaders Pee Huan Pte Ltd: authorised distributor for the HELI Forklift brand and has more than 20 years of experience in the material handling industry Sany South East Asia Pte Ltd: 3rd-largest heavy equipment manufacturer globally and one of Singapore's leading supplier offering sales, services and technical solutions in the crane industry SquareDog Robotics Limited: who will be showcasing SQD-Robo Patrol, its cost-effective, multi-functional robot that provides 24/7 security patrol for the warehouse BTA 2023 will also see returning key industry players such as Buildo Engineering Pte Ltd, Lingjack Digital Pte Ltd, PDS International Pte Ltd and SPC Industries Sdn Bhd, who are looking forward to showcasing how their latest equipment and solutions can meet evolving building and construction needs. Bridging knowledge gaps and addressing industry challenges BTA 2023 will also be launching its inaugural Built Environment Transformation Forum, where industry leaders and experts will be sharing about post-pandemic collaboration opportunities as well as trends and policies pivotal to the Built Environment Sector. Kicking off the forum is a fireside chat on sector transformation with Mr Heng Teck Thai, Deputy CEO (BuildSG Office) of the Building and Construction Authority (BCA). BTA is also working with Asia Pacific Assistive Robotics Association (APARA), World of Safety and Health Asia (WSH Asia), Singapore Contractors Association Limited (SCAL), Association of Women in Construction (AWiCS), Singapore International Facility Management Association (SIFMA) and the exhibitors, to offer six half-day conferences and over 80 conference sessions, product launches and sandboxes on the latest industry developments, technology advancements and best practices for the sector. Participants can expect insightful discussions on digitalising their operations, incorporating artificial intelligence or AI and robotics for smart construction, adopting sustainable practices, refreshing safety measures, and upgrading their knowledge in integrated facilities management. Sessions to look out for include: The update on The Accreditation of Project Managers (APM) scheme by Mr Jonathan Shek, Chairman of the Society of Project Managers, aimed at enhancing standard of project management practice in Singapore's built environment & construction industry Improving measurement accuracy with 3D laser scanning by Mr Mika Honkavuori, Entrepreneur, RECURE Establishing proper data preparation platforms to facilitate accurate retrieval of AI datasets by Mr Kevin Quah, Founder & CEO, Tictag Propelling ahead with sustainability efforts BTA 2023 is also the first event in Singapore EXPO to be piloting the sustainability measurements proof-of-concept under Singapore's MICE Sustainability Roadmap with SACEOS to measure event waste and carbon emissions. Together with Singapore EXPO, BTA will be coordinating closely with its exhibitors, suppliers and partners to identify waste drivers and boundaries, and generate actionable insights for the industry to make informed decisions to achieve net zero by 2050. Singapore EXPO, managed by Constellar, also recently announced key investment projects towards achieving Net Zero by 2024. "The pilot deployment of the sustainability measurements proof-of-concept at BTA 2023 will offer the Singapore MICE industry valuable insights and experience from diverse perspectives. These are especially important to Constellar as both an exhibition organiser and MICE venue operator, and will enable us to play a meaningful role in the MICE eco-system where collaboration with partners is the only way to reach the scale of impact needed," said Mr Jean-François Quentin, Group Chief Executive Officer, Constellar. BTA 2023 will be at Singapore EXPO Hall 3 from 28-30 March 2023. Register here to visit Find out who's exhibiting here Check out product launches and sandboxes More on the conferences here About BuildTech Asia BuildTech Asia is the Asia Pacific premier platform for the built environment sector which showcases the latest smart solutions and productive technologies across the entire building life-cycle. With international and regional brands showcasing the most comprehensive exhibiting profile such as onsite construction machinery & equipment, building materials & solutions, architectural & quality finishes, productive technologies, facilities management, and infrastructure solutions to help accelerate the built environment sector to build faster and smarter. The annual event provides a gateway into Asia to network with a wide range of practitioners, technology experts, industry players, developers, agents, and distributors in the building and construction industry. About Constellar Constellar connects a global eco-system of event partners and consumers through a holistic portfolio of intellectual property (IP) in the Meetings, Incentives, Conventions and Exhibitions (MICE) industry. As Asia's partner of reference for curating innovative event and venue experiences, Constellar activates impactful networks to bring global markets, businesses and consumers together for sustainable growth. With our expertise and dedication, we are invested in helping you build trusted relationships with stakeholders for the long term and enabling cross-industry collaboration through world-class audience engagement solutions. Visit constellar.co for more information.
-
‘Medical Korea 2023 Conference’ on Global Medical Industry Prospects to Kick off on March 23 at Coex
SEOUL, South Korea--(BUSINESS WIRE)--#COEX--The Ministry of Health and Welfare (MOHW) and the Korea Health Industry Development Institute (KHIDI) will host Medical Korea 2023 - The 13th Global Healthcare & Medical Tourism Conference at Coex in Seoul from March 23 (Thu) to March 24 (Fri), 2023. The conference will be held as a large-scale offline event, the first time in three years after the COVID-19 outbreak. Medical Korea 2023 is one of the largest global healthcare conferences in Korea with the aim of the globalization of the Korean healthcare industry. The conference begins with keynote lectures by Jamie Metzl, a technology and healthcare futurist and Hwang Hee, CEO of Kakao Healthcare. The lectures consist of 4 forums and 6 seminars covering various topics such as medical tourism trends, online training, personal health record, digital healthcare, and scale-up strategies for regional global healthcare business, in attendance of 65 speakers. Various programs such as business meetings, an exhibition (digital healthcare experience center and promotion hall for foreign patient evaluation and certification system), G2G meetings, etc. are in place to promote the discovery of channels to attract new customers through exchanges between overseas buyers and domestic sellers, and the expansion into the overseas markets by the health industry. In the forums, participants can explore the latest trends in the global healthcare industry and opportunities for health care cooperation through medical tourism policies, predict changes and innovations in health care caused by the spread of My Data, and learn the opinions of trainees from Mongolia and Uzbekistan concerning the training projects for the MKA e-class business promotion, etc. Invited experts as speakers are: Mohd Daud Mohd Arif (CEO, Malaysia Healthcare Travel Council (MHTC)) Napas Paorohitya (Chief Marketing Officer, Bumrungrad International Hospital) Hiang Khoon Tan (Director, SingHealth Duke-NUS Global Health Institute (SDGHI)) Dmytro Butov (Professor, Department of Phthisiology and Pulmonology, Kharkiv National Medical University) Kim Ju Han (Professor, College of Medicine, Seoul National University) The KHIDI has designated ‘Endemic’, ‘Telemedicine’, ‘Personal Health Record’, ‘Medical Tourism’ and ‘Digital Therapeutics (DTx)’ as the top 5 keywords for global healthcare trends in 2023. More information on Medical Korea 2023: www.mkconf.orgMajor forums at Medical Korea 2023 Conference: https://mkconf.org/fairProgram.do?selAction=single_page&program_idx=50&program_type=P&hl=ENG&FAIRMENU_IDX=12605#/ Contacts Medical Korea 2023 Hwan Guk Park +82-43-713-8972 wank21@khidi.or.kr
-
APACMed Names EVERSANA Knowledge Partner to Shape Digital Health Reimbursement Framework Across Region
SINGAPORE, March 22, 2023 /PRNewswire/ -- Asia Pacific Medical Technology Association (APACMed), the region's leading organization for medical technology manufacturers, has named EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry and a market leader in helping digital health technology innovators navigate the complexity of bringing new therapies to patients, as its knowledge partner across Asia Pacific countries. Together, the two organizations will develop a framework to support innovative reimbursement models for digital health companies as they work with policymakers to ensure better access to new and transformative therapies, diagnostic aids and patient management solutions. "We are excited to welcome EVERSANA as our knowledge partner in the APACMed Digital Health Reimbursement Alliance. With their global expertise and our shared vision for equitable access to life-saving digital health technologies, we will collaborate on building advocacy to shape the future of digital health reimbursement," said Harjit Gill, CEO of APACMed. The partnership leverages the expertise of both organizations. EVERSANA has seen rapid expansion over the past three years across the Asia Pacific region and is the industry leader in supporting the commercialization of digital health technologies globally. Meanwhile, APACMed is the largest trade association across Asia Pacific and represents more than 300 manufacturers and suppliers of medical equipment and wearable devices. "Digital innovation is the future of care across so many therapeutic categories with the potential to change how we think of healthcare today," said Jim Lang, CEO of EVERSANA. "We look forward to working with APACMed to leverage our respective expertise to help develop an important framework to drive better access for patients to therapies." About APACMed The Asia Pacific Medical Technology Association (APACMed) represents manufacturers and suppliers of medical equipment, devices and in-vitro diagnostics, industry associations and other key stakeholders associated with the medical technology industry in Asia Pacific. As a trade association, our mission is to improve the standards of care for patients through innovative collaborations among stakeholders to jointly shape the future of healthcare in Asia Pacific. The association has over 300 member organisations made up of multinational corporates, associates, digital technology, and start-up companies. To learn more visit www.apacmed.org. About EVERSANA® EVERSANA® is the leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter. MEDIA CONTACTS Matt Braun, Director, Corporate Communications, EVERSANATel: +1 414-434-4830E-mail: matt.braun@eversana.com
-
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of patients expressing CA IX. The GaLuCi™ trial is the first-in-human, multicenter, non-randomized phase 1/2 clinical trial assessing safety and tolerability, imaging characteristics and the efficacy of the theranostic pair Debio 0228/0328 in patients with unresectable, locally advanced or metastatic solid tumors. Debiopharm's research is applying precision nuclear medicine to the promising target, Carbonic Anhydrase IX (CA IX), a surface protein overexpressed in many solid tumors and a well-known marker of tumor aggressiveness and resistance to treatment. LAUSANNE, Switzerland, March 22, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™. The first patient was screened and dosed at the Australian-based Peter MacCallum Cancer Centre. This multicenter international trial, evaluating a radioligand theranostic pair will be carried out in three stages: Part A to confirm the safety and reliability of Debio 0328 in detecting CA IX-expressing solid tumors, Part B to assess escalating doses of the therapeutic agent, Debio 0228 in patients, whose tumors show high uptake of Debio 0328 and finally, based on the recommended dose from part B, Part C will further assess safety and preliminary efficacy in selected tumor types. Currently, Debio 0228/0328 is the only peptide-based theranostic pair targeting CA IX in clinical development, with pan-tumor potential, and developed first for patients with advanced cancers such as renal, pancreatic, and colorectal. It leverages a theranostic approach to identify and deliver radiation to diseased tissues, allowing the imaging-based pre-identification of patients who have the target proteins necessary to respond to the targeted radioligand. "The results of the GaLuCi™ trial are highly anticipated considering the therapeutic potential of Debio 0228 as observed in preclinical models. Using this theranostic pair could pave the way for personalized nuclear medicine, enabling administration of the lutetium coupled radioligand only to patients who are more likely to respond to the therapy." explained Angela Zubel, Chief Development Officer at Debiopharm. "We always have immense gratitude for our patients who participate in first time in human trials, but in this case, we are particularly thankful for our patient who agreed to be the first person in the world to have their kidney cancer imaged with Debio 0328 on the GaLuCi™ trial. We hope this is the beginning of the theranostics era in kidney cancer!" expressed Dr. Ben Tran, Lead Genito-urinary medical oncologist, Peter MacCallum Cancer Centre. "We are excited about this first-in-human study as it is a novel approach for advanced kidney cancer patients," said Darren R. Feldman, MD, Associate Attending Physician, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. "Precision nuclear medicine applied to CA9 could benefit advanced cancer patients who still experience a high unmet medical need. This theranostic pair allows targeted radiation delivery to the cancer cells bearing CA IX, which is largely expressed, over 85%, in clear cell renal cell carcinoma." The theranostic approach with Debio 0228/0328Debio 0228 ([177Lu]Lu-DPI-4452) and 0328 ([68Ga]Ga-DPI-4452) is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and exclusively licensed to Debiopharm. ([68Ga]Ga-DPI-4452 is a PET imaging agent, (Debio 0328) used to identify patients whose cancers overexpress CA IX. Once identified, these patients can be treated with the lutetium-labelled radioligand, Debio 0228, which delivers targeted radiation to the tumor, destroying it from the inside. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit www.debiopharm.com We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews Debiopharm Contact Dawn BonineHead of Communicationsdawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11
-
Casio to Release New EDIFICE Incorporating Design Features from the NISMO Ace Racing Car
Design Employs Graphic Elements from the #23 Nissan Z, which Competes in Japan's Most Prestigious Motorsport Race TOKYO, March 22, 2023 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the release of the latest addition to the EDIFICE line of timepieces based on the brand concept of "Speed and Intelligence." The ECB-2000NIS, named the NISMO MY23 EDITION to signify "Model Year 2023," is clad in graphics from the NISMO works team's ace race car. ECB-2000NIS NISMO is a works team of Nissan Motor Co., Ltd. that engages in motorsport activities. The EDIFICE line of high-performance timepieces inspired by a motorsports worldview has been a NISMO supporter since 2021. The two brands are natural allies that share a passion for leveraging cutting-edge technology in pursuit of ultimate performance. The new ECB-2000NIS is a high-performance chronograph that incorporates design elements from the body of the NISMO works team's #23 Nissan Z race car that has been competing in Japan's most prestigious motorsport race, the SUPER GT. The new watch is based on the EDIFICE ECB-2000, which features a carbon fiber-reinforced resin case and a unique race car suspension-inspired design. Modeled after the color scheme of the race car as viewed from the side, the entire watch features a two-tone shift from red in the 12 o'clock direction to black in the 6 o'clock direction. A graphic pattern interlacing with the "Z" logo appearing on the car is incorporated into the dial design in the upper section. The number of the Nissan/NISMO ace car, "23," adorns the 23-minute position. A section of the bezel's edge is tapered to create a sharp curved-line form inspired by the roofline of the car, which evokes the look of a Japanese sword. Such elements from the body of the car are expressed in multiple aspects of the watch design. Entire watch features a two-tone shift from red to black / Graphic pattern interlacing with “Z” logo on the dial’s upper half More information: https://www.casio.com/intl/news/2023/0322-ecb-2000nis/
-
DRAFTKINGS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DraftKings Inc. and Encourages Investors to
NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against DraftKings Inc. (“DraftKings” or the “Company”) (NASDAQ: DKNG) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired DraftKings securities between August 11, 2021 and the present, both dates inclusive (the “Class Period”). Investors have until May 8, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the NFTs were securities for which DraftKings unlawfully failed to file a registration statement; (2) DraftKings ensured that money invested by class members stayed on DraftKings' private and exclusively controlled marketplace, propping up the market for and overall valuation of DraftKings' NFTs; and (3) as a result, investors have suffered significant damages. When the true details entered the market, the lawsuit claims that investors suffered damages. If you purchased or otherwise acquired DraftKings shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.comwww.bespc.com
-
FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Enco
NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). Investors have until March 22, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Fate is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders. On April 2, 2020, after the market closed, Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the “Janssen Collaboration Agreement”). In addition, Fate was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. On the news, Fate’s stock price jumped 8.8% in trading on April 3, 2020. Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. On January 5, 2023, after the markets closed, Fate issued a press release announcing that it had terminated the Janssen Collaboration Agreement. Specifically, the Company disclosed that it was “not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023[.]” As a result of the termination, Fate revealed that all licenses and other rights granted pursuant to the Janssen Collaboration Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers, including FT516 and FT538 NK cell programs in acute myeloid leukemia, FT516 and FT596 NK cell programs in B-cell lymphoma, and FT538 and FT536 NK cell programs in solid tumors. On this news, Fate’s stock price fell $6.76 per share, or 61.45%, to close at $4.24 per share on January 6, 2023. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages. If you purchased or otherwise acquired Fate shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.comwww.bespc.com
-
ABLIC Launches the S-19114 Series of Automotive High Withstand Voltage Battery Monitoring ICs Combining the Industry’s Fastest (*1) Voltage Detection
Helps Improve System Safety and Lowers Cost TOKYO--(BUSINESS WIRE)--ABLIC (President: Nobumasa Ishiai, head office: Minato-ku, Tokyo hereinafter “ABLIC”), a group company of MinebeaMitsumi Inc., today launched the S-19114 Series of automotive high withstand voltage battery monitoring ICs with the industry’s fastest (*1) voltage detection response. The S-19114 Series launched today is a battery monitoring IC that operates at 36V and has the industry’s fastest detection response time of Max. 10μs (*2). Two components impact the detection response time: the resistance components and the capacitance components in the IC. However, they are not much of a problem as the resistance components of the S-19114 Series are 1/5 of earlier models and capacitance components have been reduced to such an extent that detection response time is 1/20 of earlier models. The S-19114 Series have few resistance and capacitance components that impact detection response time and current consumption during operation is a low 2.0µA typ. This makes the series ideal for low standby current systems where continuous sensing is required. Another advantage is that the S-19114 Series is housed in the ultra-compact package making it a product that amply meets today’s need for smaller automotive devices. (*1) As a battery monitoring IC for 36V operation. Based on our research as of March 2023 (*2) 1/20 the detection time of our previous products Major Features 1. Shorter voltage detection response times as well as low current consumption 2. Smaller footprint through ultra-compact HSNT-6(2025) (1.96 x 2.46 x t0.5mm) package 3. The monitoring voltage input pin (SENSE pin) has a wide rated voltage of -30V to 45V 4. Automotive quality These products have been subjected to the three-temperature test (low, normal and high temperature). According to the AEC (Automotive Electronics Council), this series will comply with AEC-Q100 Grade 0 reliability and quality test defined by the Council. They are also in compliance with the Production Part Approval Process (PPAP). Application Examples Voltage detection of automotive batteries Automotive components such as engines, transmissions, suspensions or ABS as well as EV, HEV or PHEV vehicle parts S-19114 Series Product Details https://www.ablic.com/en/semicon/products/automotive/automotive-voltage-detector-reset-ic/s-19114xxxa/ Website https://www.ablic.com/ This product has been certified as a MinebeaMitsumi Group "Green Product" for its outstanding contribution to the environment. Contacts ABLIC Inc. Masae Onuma pr@ablic.comhttps://hub.ablic.com/en/pr-inquiry?rf=support
-
Rio Tinto becomes first major mining company to publish site-by-site water usage data
LONDON--(BUSINESS WIRE)--Rio Tinto is marking World Water Day 2023 by making public detailed information about annual surface water usage across its global network of managed sites in 35 countries, through an interactive map on its website riotinto.com/water. For each managed site included, the database details permitted surface water allocation volumes, the site’s annual allocation usage and the associated catchment runoff from average annual rainfall estimate. The database includes five-year historic comparative data and will be updated annually. In 2019 Rio Tinto made a commitment to drive good water stewardship and improve disclosure to stakeholders, by publishing site-by-site surface water usage data for all managed sites by the end of 2023. This commitment is in line with the water reporting guidelines of the International Council on Mining and Metals (ICMM) Water Stewardship Position Statement, which sets out ICMM members’ approach to water stewardship. It includes commitments requiring members to apply strong and transparent water governance, manage water at operations effectively, and collaborate to achieve responsible and sustainable water use. Rio Tinto Chief Executive Jakob Stausholm said “Water is an essential resource, critical to sustaining biodiversity, people, and economic prosperity. It is also a resource we share with the communities and nature surrounding our operations, so it is essential that we carefully manage our use and hold ourselves accountable to our stakeholders. “This interactive database brings a new level of transparency and will enable us to engage more deeply with our stakeholders, seek their feedback on our disclosure and continue to focus our efforts on becoming better water stewards for today and future generations.” Sharing water with communities and nature surrounding operations means balancing operational needs with those of the local communities and ecosystems. Rio Tinto aims to avoid permanent impacts on water resources by carefully managing the quality and quantity of the water used and returned to the environment. We will look to incorporate future water and broader environmental disclosures within this platform. The interactive platform and full details of Rio Tinto’s approach to water are available at riotinto.com/water. The latest Rio Tinto sustainability disclosures are available in the 2022 Sustainability Fact Book at riotinto.com/sustainabilityreporting. riotinto.com Contacts Please direct all enquiries to media.enquiries@riotinto.com Media Relations,United Kingdom Matthew KlarM +44 7796 630 637 David OuthwaiteM +44 7787 597 493 Media Relations,Australia Matt ChambersM +61 433 525 739 Jesse RiseboroughM +61 436 653 412 Alyesha AndersonM +61 434 868 118 Media Relations,Americas Simon LetendreM +1 514 796 4973 Malika CherryM +1 418 592 7293 Investor Relations,United Kingdom Menno SanderseM +44 7825 195 178 David OvingtonM +44 7920 010 978 Clare PeeverM +44 7788 967 877 Investor Relations,Australia Tom GallopM +61 439 353 948 Amar JambaaM +61 472 865 948 Category: General
-
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--$KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about March 24, 2023, subject to customary closing conditions. In addition, Karuna has granted the underwriters a 30-day option to purchase up to an additional 371,908 shares of common stock. All the shares in the offering are being sold by Karuna. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Inc. and Guggenheim Securities, LLC are also acting as book-running managers for the offering. The shares are being offered by Karuna pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement relating to these securities may also be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Karuna Therapeutics Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Forward Looking Statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including among other things, the timing and completion of the public offering, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, market risks and the satisfaction of customary closing conditions for an offering of securities. These and other risks are described under the heading “Risk Factors” in Karuna’s most recent Annual Report on Form 10-K filed with the SEC and in other filings that Karuna makes with the SEC. Karuna’s actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, Karuna undertakes no obligation to update or revise these forward-looking statements. Contacts Investors:Alexis Smith +1 (518) 338-8990 asmith@karunatx.com Media:Bob Josefsberg +1 (646) 734-3584 bjosefsberg@karunatx.com
-
HSAI INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Hesai Group and Encourages Investors with Substantial Losses o
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential violations of U.S. federal securities laws by Hesai Group (NASDAQ: HSAI) focused on whether Hesai Group and certain of its top executive officers made false and misleading statements and/or failed to disclose material information to investors. If you have information that could assist in this investigation or if you are a Hesai Group investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-hesai-group-securities-investigation-hsai.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. THE COMPANY: Hesai Group is a Chinese manufacturer of light detection and ranging (“LiDAR”) products for robots and autonomous vehicles. On February 9, 2023, Hesai Group conducted an initial public offering, selling over 10.12 million American Depository Receipts (“ADRs”) (including the partial exercise of the over-allotment option) at $19.00 per ADR for more than $192 million in gross offering proceeds (the “IPO”). THE REVELATION: Barely one month later, on March 16, 2023, Hesai Group reported its unaudited financial results for the three months and full year ended December 31, 2022 – the quarter prior to the IPO. In doing so, Hesai Group disclosed that it had suffered a decrease in gross margin compared to the fourth quarter 2021 due to “increased shipments of lower-margin [advanced driver assistance systems] LiDAR products . . . with lower in-house plant capacity utilization rate.” Following this news, the price of Hesai Group ADRs fell to less than $12.00 per ADR, 37% below the IPO price. ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contacts Robbins Geller Rudman & Dowd LLP 655 W. Broadway, Suite 1900, San Diego, CA 92101 J.C. Sanchez, 800-449-4900 jsanchez@rgrdlaw.com
-
NILE 'NEITH Station': the world's first WEMIX mega-ecosystem NFTFi
NEITH NFTs is the world's first NFT that conveys value via an underlying asset Can be purchased with WEMIX$ from Marketplace Bears WEMIX which can be claimed on Convenant date First two collectibles are 'City of NILE' and 'Tangled Timepieces' NEW YORK, March 22, 2023 /PRNewswire/ -- Wemade's DAO & NFT platform NILE (NFT Is Life Evolution) has officially launched "NEITH Station", the world's first NFTFi service that guarantees stable future value via NEITH NFTs. These combine NFTs and DeFi to enable NFTFi, a decentralised protocol that facilitates Lending, Swaps, Staking, and more. The world's first NFT that conveys value via an underlying asset, NEITH NFTs are a new type of NFT that bears WEMIX and can be purchased with WEMIX$ in the Marketplace via auction or fixed-price sales. NFTs can be traded freely up till the Claim which can be made any time after the Covenant Date. This is usually set for one year after the start of the sale and only NFT holders can claim the covenant amount of WEMIX on or after the Covenant Date. Holders can also engage and communicate with others who own the same collection to increase the value of their NFTs through collective potential. Launched on March 16, City of NEITH is the first PFP (profile picture) collectible in the City of NILE collection consisting of 10 cities, each with 88 NFTs. City of Nile's 88 NEITH NFTs are divided into five grades: Civic, Rare, Epic, Legendary, and Mythical. Depending on the grade, it can be purchased at a fixed price or through an open auction system. On March 23, NEITH Station will launch the 'Tangled Timepieces' NEITH NFT collectible, its first T2E (Talk to Earn) collectible which comes with the 'Tangled' companion app. Tangled Timepieces is a collection of NEITH NFTs that can store time points earned in the Tangled app. You can purchase LUXURY grade NEITH NFTs in the Marketplace, and you can obtain a higher, High-End, Zenith grade by synthesising the purchased NFTs. When synthesised to a higher grade, the promised Wemix (Neith Covenant) is also merged. Links: NILE (NFT Is Life Evolution): https://www.nile.io/ NEITH Station: https://www.nile.io/neith-station City of NILE: https://www.nile.io/life/cone Tangled Timepieces: https://www.nile.io/life/tangled About WEMADE A renowned industry leader in game development with over 20 years of experience, Korea-based WEMADE is leading a once-in-a-generation shift as the gaming industry pivots to blockchain technology. Through subsidiary WEMIX, WEMADE aims to accelerate the mass adoption of blockchain technology by building an experience-based, platform-driven, and service-oriented mega-ecosystem to offer a wide spectrum of intuitive, convenient, and easy-to-use Web3 services. www.wemade.com About NILE NILE is the world's first DAO-powered blockchain NFT platform based on a fully decentralized smart contract infrastructure that will redefine the way we identify and express inspiration, creativity, and opportunity. NILE enables trustless and transparent projects in the form of concerts, art exhibits, sports, music, investments, and even businesses to be facilitated and managed through the DAO. More at www.nile.io
-
Yugabyte Announces Speaker Lineup for Third Annual Distributed SQL Summit Asia
Experts and Executives from Tokopedia, Airwallex, Novopay, Red Hat and Mindgate to Present at the Virtual Event SUNNYVALE, Calif.--(BUSINESS WIRE)--#DSSAsia--Yugabyte, the leading open source distributed SQL database company, today announced the speaker lineup for the upcoming third annual Distributed SQL Summit (DSS) Asia. This year’s virtual summit, taking place on Tuesday, March 28, includes speakers from companies including Tokopedia, Airwallex, Novopay, Red Hat, Mindgate, Yugabyte, and more. Registration to DSS Asia is free and the full speaker schedule is available here. DSS Asia brings together Yugabyte’s Asian community of executives, developers, partners, customers, and industry experts to share use cases and best practices for building cloud-native applications and driving database modernization with distributed SQL. “This is our third DSS Asia event, and it’s been inspiring to watch as every year attendance gets bigger, use cases become more innovative, and the general buzz increases as the adoption of distributed SQL accelerates,” said Karthik Ranganathan, co-founder and CTO of Yugabyte. “This year, the event features speakers that are using distributed SQL in incredibly exciting ways – from solving global banking challenges to overcoming roadblocks in database modernization strategy – it’s going to be a great event.” DSS Asia features three tailored talk tracks—Technology, Japan, and Customers & Partners – with each session offering something for every level of interest, from technical expertise to general business value. Yugabyte CTO and co-founder, Karthik Ranganathan, will also give the keynote presentation, titled “Embrace, Extend, Evolve - Making PostgreSQL work for a Cloud Native World.” Additional speakers at DSS Asia 2023 include: Ahilan Ponnusamy, GTM Specialist, Red Hat Lalit Chowdhary, Senior Vice President, Mindgate Feixiang Zhao, Database Architect, Airwallex Felix Christian Jonathan, Technical Architect, Tokopedia Vish Phaneedra, Head of Solutions Engineering, Yugabyte Manoj Mathew, Chief Architect, Novopay Participants of DSS Asia will have the opportunity to join free YugabyteDB University training courses and certification testing on the topics of YCQL Development, YSQL Development, and YugabyteDB Administration. Distributed SQL Summit Asia is the first of Yugabyte’s 2023 DSS events. You can find more information on upcoming events and DSS days here. Click here to register for DSS Asia 2023 and join the conversation on Twitter at #DSSAsia. About Yugabyte Yugabyte is the company behind YugabyteDB, the open source, high-performance distributed SQL database for building global, cloud-native applications. YugabyteDB serves business-critical applications with SQL query flexibility, high performance and cloud-native agility, thus allowing enterprises to focus on business growth instead of complex data infrastructure management. It is trusted by companies in cybersecurity, financial markets, IoT, retail, e-commerce, and other verticals. Founded in 2016 by former Facebook and Oracle engineers, Yugabyte is backed by Lightspeed Venture Partners, 8VC, Dell Technologies Capital, Sapphire Ventures, and others. www.yugabyte.com Contacts Allison Stokes fama PR yugabyte@famapr.com
-
Presidio Medical™ Announces Executive Appointment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#chronicpain--Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer. Mr. Salys is a 25-year veteran in Class III active implantable devices leading R&D, Operations, Supply Chain, Program Management, and Durable Medical Equipment (DME) organizations. Mr. Salys joins Presidio from Abbott where he was most recently the Divisional Vice President of R&D of the Heart Failure business. “We are thrilled to have someone with Scott’s breadth of experience across Operations, Supply Chain, and R&D join the Presidio team. Not only does Scott have functional expertise in key areas for Presidio’s progression, but he has managed several business lines within cardiac rhythm management and neuromodulation, which is complimentary to the platform Presidio is building,” said Michael Onuscheck, Chairman and CEO of Presidio Medical. “I am excited to join this incredibly talented team and lead Presidio Medical through the next stage of clinical and product development. We have the unique opportunity to create neuromodulation therapies for new patient populations as well as transform conventional neuromodulation therapy. I am passionate about building high-performing teams and look forward to delivering our novel ULF platform to patients,” said Mr. Salys. Prior to joining Presidio Medical, Mr. Salys was the Divisional Vice President of R&D (2021 to 2022) and Divisional Vice President of Operations (2017 to 2021) in Abbott’s Heart Failure business, where he led the organization through a phase of rapid growth and expansion. In addition to roles in R&D and Operations, Mr. Salys transformed the Heart Failure DME business by shifting strategy, building the team, and establishing a commercial organization that delivered triple digit growth. Mr. Salys also served on Abbott’s Executive Crisis Management Team, Scientific Governing Board, as well as the Board of Directors for Abbott Global Enterprises. Prior to Abbott’s acquisition of St. Jude Medical (SJM) in 2017, Mr. Salys spent over 16 years at SJM in R&D, Operations, and Supply Chain roles across various divisions and geographies. Scott’s most recent roles at SJM included Vice President of Operations and R&D, VP of Supply Chain, VP of Operations, and VP of Program Management. Mr. Salys successfully integrated newly acquired businesses, strengthened global organizations, executed change management initiatives, and delivered rapid growth in the neuromodulation and cardiac resynchronization therapy markets. ABOUT PRESIDIO MEDICAL Presidio Medical was founded in 2017 and is headquartered in South San Francisco, CA. The clinical-stage, privately held medical device company is developing a transformational neuromodulation platform to treat diseases of undesired neural activity with a first indication in the treatment of chronic pain. Presidio’s current investors include Invus Opportunities and Action Potential Venture Capital. For more information, visit www.presidiomedical.com. Contacts Presidio Medical, Inc. media@presidiomedical.com650-502-1071
-
Educational Media Foundation Announces CEO Transition
Todd Woods named CEO by Board of Directors as Bill Reeves departs organization NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Educational Media Foundation’s (EMF) Board of Directors announced that CEO Bill Reeves will depart EMF and Todd Woods was elected CEO by the Board of Directors. “The Board of Directors and the Ministry Leadership Team would like to thank Bill for his work and contributions to EMF’s mission,” Donna Ecton, Board Chair said. “We appreciate his years of service to the Christian media industry. We wish him well in his future endeavors.” Since joining EMF, Woods has served the organization with distinction, including as Chief Legal Officer, Corporate Secretary, Head of External Affairs and Chair of the Strategic Planning Committee. Woods has helped lead some of the world’s most renowned organizations and has served on the Board of Directors for more than 10 domestic and international organizations. “I’m honored by the trust the Board of Directors has placed in me to lead EMF,” Woods said. “We have a tremendous team here. I look forward to leading the organization as we continue to create, produce and share compelling media with God’s life-changing message while our EMF care ministries connect with our audiences to support and inspire them in their faith journey.” “The Board of Directors is confident that Todd’s expertise, strategic vision and team building approach will lead EMF to continued success,” Ecton said. “Our faith-focused audiences, donors, artists and partners put their trust in EMF because of how we use God’s Word to guide our decisions. The Board of Directors looks forward to Todd’s leadership where he will continue the organization’s focus on its founding mission.” About Educational Media Foundation Educational Media Foundation (EMF) is a nonprofit, multi-platform media company on a mission to draw people closer to Christ. Founded in 1982 in Santa Rosa, Calif., with a single radio station, EMF today owns and operates the world’s two largest Christian music radio networks (K-LOVE and Air1) with more than 1,000 broadcast signals across all 50 states, streaming audio reaching around the world, and a growing family of media ministries including podcasts, books, films, concerts and events. EMF employs 500 team members between its offices in Nashville, TN; Rocklin, CA; and field locations around the country. (For more information, visit www.emfbroadcasting.com) Contacts Media Contact: Rory McKean, rmckean@kloveair1.com – 334.549.1850
-
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against United Natural Foods, Inc. (UNFI)
SAN DIEGO--(BUSINESS WIRE)--$UNFI #UNFI--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired United Natural Foods, Inc. (NYSE: UNFI) securities between March 10, 2021 and March 7, 2023, for violations of the Securities Exchange Act of 1934. United Natural Foods is a distributor of natural, organic, specialty, produce, and conventional grocery and non-food products. What Now: Similarly situated shareholders may be eligible to participate in the class action against United Natural Foods. Shareholders who want to act as lead plaintiff for the class must file their papers by May 19, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. What is this Case About: United Natural Foods, Inc. (UNFI) Made False and Misleading Statements Regarding its Business Prospects According to the complaint, on March 8, 2023, United Natural Foods announced its second quarter 2023 financial results, revealing a $6 million decline in gross profits, despite a 6% increase in net sales. The Company stated that its profits “were challenged as we did not repeat the significant level of procurement gains from rapidly accelerating inflation and inventory gains, due to supply chain volatility, that we experienced in the second quarter of last year.” On this news, the Company’s stock price fell $11.49, or 28.1%, to close at $29.47 per share on March 8, 2023, injuring investors. During the class period, defendants failed to disclose to investors: (1) that, despite its cost saving Value Path initiative, United Natural Foods had not invested in improving its data management and related infrastructure; (2) that, as a result, the Company could not respond adequately to cost changes, such as inflationary pressure; (3) that, as a result, the Company could not appreciate the benefits of procurement gains and inventory gains achieved during fiscal 2022; and (4) that, as a result of the foregoing, the Company’s profitability would be materially adversely impacted. Contact us to learn more: Aaron Dumas (800) 350-6003 adumas@robbinsllp.comShareholder Information Form About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against United Natural Foods settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contacts Aaron Dumas Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com(800) 350-6003 www.robbinsllp.com
-
Ecolomondo Announces the Grant of Stock Options to Purchase 1,450,000 Common Shares
NOT FOR DISTRIBUTION TO U.S NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL--(BUSINESS WIRE)--Ecolomondo Corporation (TSX-V: ECM) (the “Company” or “Ecolomondo”), a cleantech company specializing in the commercialization of its Thermal Decomposition Process (“TDP”) proprietary recycling technology and the deployment of TDP turnkey facilities, announces that pursuant to the Company's Stock Option Plan, the Company has granted stock options (the “Options”) to certain directors and officers to purchase an aggregate of 1,450,000 common shares of the Company at an exercise price of $0.3525 per share for a period of ten years from the date of grant. The Options will vest over a period of one (1) year (1/2 on the date that is six months from the date of grant, and 1/2 based on performance, attendance and participation on the date that is 12 months from the date of grant). The Options are subject to approval of the TSX Venture Exchange. About Ecolomondo Corporation Ecolomondo Corporation is a Canadian cleantech company that prides itself after its proprietary Thermal Decomposition technology TDP which is headquartered in Québec, Canada. It has a 25-year history and during this time has been focused on its development of its technology and the deployment of TDP turnkey facilities. TDP recovers high value re-usable commodities from scrap tire waste, notably rCB, oil, syngas, fiber and steel. Ecolomondo expects to be a leading player in the cleantech space and be an active contributor to the global circular economy. Ecolomondo trades on the TSX Venture Exchange under the symbol (TSXV:ECM). To learn more, visit www.ecolomondo.com Our Mission, Vision & Strategy Ecolomondo’s mission is to be a contributing participant in a dynamic Circular Economy and to increase shareholder value by producing and supplying large quantities of recovered resources to be re-used in the manufacture of new products. Ecolomondo’s vision is to be a leading producer and reseller of recovered resources by building and operating TDP facilities, strategically located in industrialized countries, close to feedstock, labor and offtake clients. Our strategy is to become a major global builder and operator of TDP turnkey facilities, for now specializing in the processing of ELTs. Our intent is to expand aggressively in North America and Europe. Our experience and modular technology should help us get there faster and better. We plan to keep performing ongoing research and development to ensure that Ecolomondo remains technologically advanced. About TDP The TDP process is technically proven and more advanced than most other pyrolysis technologies. Over the years, our Technological teams were able to overcome all uncertainties that plagued most competitors especially in these areas: pre-filtration, reactor cooling, reactor rotation, reactor evacuation, water recycling, cleaning of rCB, (hydrocarbon removal), mass monitoring, heat curve development, humidity and water removal, safety testing, system automation, emissions control and monitoring, rCB and pyrolysis oil post processing, efficient syngas reuse. TDP is Environmentally Friendly – CO2 Reduction By producing rCB, TDP reduces GHG emissions by 90% versus the production of virgin carbon black. The production of rCB at the Hawkesbury and Shamrock facilities are expected to reduce CO2 emissions by 22,400 and 67,200 tons per year, respectively. Please follow Ecolomondo on Twitter, Facebook, LinkedIn, Instagram and YouTube. Twitter: https://twitter.com/EcolomondoECMFacebook: https://www.facebook.com/EcolomondoECMLinkedIn: https://www.linkedin.com/company/ecolomondo/Instagram: https://www.instagram.com/ecolomondoecm/YouTube: https://www.youtube.com/@Ecolomondo Cautionary Note Regarding Forward Looking Statements The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Although Ecolomondo believes that the expectations reflected in forward looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, Ecolomondo disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release Contacts Ecolomondo CorporationEliot Sorella Chairman and Chief Executive Officer, Ecolomondo Tel: (450) 587-5999 esorella@ecolomondocorp.comwww.ecolomondo.com
